Emerging company Brii Biosciences has signed a new series of partnerships, all with US-based ventures, to develop and commercialize in greater China a portfolio of novel anti-infective agents for serious drug-resistant and difficult-to-treat pathogens.
The deals double-down the China-focused start-up’s tight strategic focus on an area where it sees much outstanding need despite big...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

